 The U.K. Medicines and Healthcare Products Regulatory Agency MHRA has approved GW Pharmaceuticals cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex TSC for patients two years of age and older. GW is a part of Jazz Pharmaceuticals plc NASDAQ: JAZZ. 